AU2016294417B2 - Anti-CD154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy - Google Patents

Anti-CD154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy Download PDF

Info

Publication number
AU2016294417B2
AU2016294417B2 AU2016294417A AU2016294417A AU2016294417B2 AU 2016294417 B2 AU2016294417 B2 AU 2016294417B2 AU 2016294417 A AU2016294417 A AU 2016294417A AU 2016294417 A AU2016294417 A AU 2016294417A AU 2016294417 B2 AU2016294417 B2 AU 2016294417B2
Authority
AU
Australia
Prior art keywords
ser
antibody
disease
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016294417A
Other languages
English (en)
Other versions
AU2016294417A1 (en
Inventor
Arron HEARN
Robert George Edward Holgate
Jay ROTHSTEIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunext Inc
Original Assignee
Immunext Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunext Inc filed Critical Immunext Inc
Publication of AU2016294417A1 publication Critical patent/AU2016294417A1/en
Application granted granted Critical
Publication of AU2016294417B2 publication Critical patent/AU2016294417B2/en
Priority to AU2022263520A priority Critical patent/AU2022263520B2/en
Priority to AU2025226796A priority patent/AU2025226796A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
AU2016294417A 2015-07-14 2016-07-13 Anti-CD154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy Active AU2016294417B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2022263520A AU2022263520B2 (en) 2015-07-14 2022-11-02 Anti-CD154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy
AU2025226796A AU2025226796A1 (en) 2015-07-14 2025-09-05 Anti-CD154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562192269P 2015-07-14 2015-07-14
US62/192,269 2015-07-14
US201562197966P 2015-07-28 2015-07-28
US62/197,966 2015-07-28
US201662277201P 2016-01-11 2016-01-11
US62/277,201 2016-01-11
PCT/US2016/042074 WO2017011544A1 (en) 2015-07-14 2016-07-13 Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022263520A Division AU2022263520B2 (en) 2015-07-14 2022-11-02 Anti-CD154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy

Publications (2)

Publication Number Publication Date
AU2016294417A1 AU2016294417A1 (en) 2018-03-08
AU2016294417B2 true AU2016294417B2 (en) 2022-08-04

Family

ID=57757587

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016294417A Active AU2016294417B2 (en) 2015-07-14 2016-07-13 Anti-CD154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy
AU2022263520A Active AU2022263520B2 (en) 2015-07-14 2022-11-02 Anti-CD154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy
AU2025226796A Pending AU2025226796A1 (en) 2015-07-14 2025-09-05 Anti-CD154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2022263520A Active AU2022263520B2 (en) 2015-07-14 2022-11-02 Anti-CD154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy
AU2025226796A Pending AU2025226796A1 (en) 2015-07-14 2025-09-05 Anti-CD154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy

Country Status (27)

Country Link
US (3) US10874738B2 (enExample)
EP (2) EP3331548B8 (enExample)
JP (4) JP6826113B2 (enExample)
KR (2) KR20250099272A (enExample)
CN (2) CN114671952A (enExample)
AU (3) AU2016294417B2 (enExample)
CL (1) CL2018000103A1 (enExample)
CO (1) CO2018001363A2 (enExample)
CR (1) CR20180097A (enExample)
DK (1) DK3331548T3 (enExample)
DO (1) DOP2018000018A (enExample)
EA (1) EA201890297A1 (enExample)
EC (1) ECSP18009949A (enExample)
ES (1) ES3075638T3 (enExample)
FI (1) FI3331548T3 (enExample)
GT (1) GT201800018A (enExample)
IL (3) IL310460A (enExample)
LT (1) LT3331548T (enExample)
MX (2) MX2018000548A (enExample)
MY (2) MY203911A (enExample)
PE (1) PE20180741A1 (enExample)
PH (1) PH12018500098A1 (enExample)
PT (1) PT3331548T (enExample)
RS (1) RS68307B1 (enExample)
SG (1) SG10201913431QA (enExample)
TN (1) TN2018000021A1 (enExample)
WO (1) WO2017011544A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024222895A1 (zh) 2023-04-28 2024-10-31 信达生物制药(苏州)有限公司 抗cd40l抗体及其在人自身免疫疾病治疗的应用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913431QA (en) * 2015-07-14 2020-03-30 Immunext Inc Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy
CA3006398A1 (en) 2015-11-27 2017-06-01 Ablynx Nv Polypeptides inhibiting cd40l
WO2019195770A1 (en) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
WO2020056162A1 (en) * 2018-09-12 2020-03-19 Oregon Health & Science University Detecting and/or subtyping circulating hybrid cells that correlate with stage and survival
WO2020068723A1 (en) * 2018-09-24 2020-04-02 Janssen Biotech, Inc. Method of providing safe administration of an anti-cd154 antibody
CN115227824A (zh) * 2018-11-12 2022-10-25 中南大学湘雅二医院 免疫检查点的抑制剂在制备治疗青光眼和其他眼部免疫损伤机制相关疾病药物中的应用
CA3136725A1 (en) * 2019-04-12 2020-10-15 Tonix Pharmaceuticals Holding Corp. Inhibitors of cd40-cd154 binding
AU2020358854B2 (en) * 2019-10-03 2026-08-13 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
CN113488170B (zh) * 2021-07-02 2023-07-25 温州医科大学 急性前葡萄膜炎复发风险预测模型构建方法及相关设备
WO2023008982A1 (ko) * 2021-07-30 2023-02-02 서울대학교산학협력단 항 cd154 항체 및 이의 용도
EP4382537A4 (en) * 2021-07-30 2025-07-23 Seoul Nat Univ R&Db Foundation ANTI-CD154 ANTIBODY AND ITS USE
WO2024211211A1 (en) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies
US20240392022A1 (en) 2023-05-22 2024-11-28 Genzyme Corporation Treatment of multiple sclerosis with anti-cd40l antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012566A1 (en) * 1997-09-08 1999-03-18 Idec Pharmaceuticals Corporation HUMANIZED ANTIBODIES TO HUMAN gp39, COMPOSITIONS CONTAINING AND THERAPEUTIC USE THEREOF
US20060147446A1 (en) * 1995-11-07 2006-07-06 Amelia Black Humanized antibodies to human GP39, compositions, and therapeutic uses thereof
WO2008118356A2 (en) * 2007-03-22 2008-10-02 Biogen Idec Ma Inc. Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
US20130136734A1 (en) * 2011-04-04 2013-05-30 The Trustees Of Dartmouth College ANTI-CD154 ANTIBODIES HAVING IMPAIRED FcR BINDING AND/OR COMPLEMENT BINDING PROPERTIES AND RELATED THERAPIES

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1127351C (zh) 1993-09-02 2003-11-12 达特茅斯学院理事 诱导抗原特异性ｔ细胞耐受的方法
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6444018B1 (en) 1998-06-25 2002-09-03 Xerox Corporation Phase change ink carrier compositions containing anhydride/amino alcohol-based adducts
GB0006398D0 (en) * 2000-03-16 2000-05-03 Novartis Ag Organic compounds
NZ525793A (en) 2000-10-13 2008-04-30 Biogen Idec Inc Humanized anti-LT-beta-R antibodies
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
DK1639014T3 (da) 2003-06-13 2011-01-17 Biogen Idec Inc Aglycosyl-anti-CD154 (CD40-ligand)-antistoffer og anvendelser deraf
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
US20110123440A1 (en) 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
WO2012138768A2 (en) * 2011-04-04 2012-10-11 Trustees Of Dartmouth College Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and the use thereof in immune therapies
SG10201913431QA (en) * 2015-07-14 2020-03-30 Immunext Inc Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060147446A1 (en) * 1995-11-07 2006-07-06 Amelia Black Humanized antibodies to human GP39, compositions, and therapeutic uses thereof
WO1999012566A1 (en) * 1997-09-08 1999-03-18 Idec Pharmaceuticals Corporation HUMANIZED ANTIBODIES TO HUMAN gp39, COMPOSITIONS CONTAINING AND THERAPEUTIC USE THEREOF
WO2008118356A2 (en) * 2007-03-22 2008-10-02 Biogen Idec Ma Inc. Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
US20130136734A1 (en) * 2011-04-04 2013-05-30 The Trustees Of Dartmouth College ANTI-CD154 ANTIBODIES HAVING IMPAIRED FcR BINDING AND/OR COMPLEMENT BINDING PROPERTIES AND RELATED THERAPIES

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIRK, A.D. et al., "Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates", Nature Medicine. 1999, Vol. 5, No. 6, pages 686 - 693 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024222895A1 (zh) 2023-04-28 2024-10-31 信达生物制药(苏州)有限公司 抗cd40l抗体及其在人自身免疫疾病治疗的应用

Also Published As

Publication number Publication date
KR20250099272A (ko) 2025-07-01
AU2022263520B2 (en) 2025-06-05
IL297907A (en) 2023-01-01
IL310460A (en) 2024-03-01
WO2017011544A1 (en) 2017-01-19
CA2992116A1 (en) 2017-01-19
EP4732909A2 (en) 2026-04-29
CR20180097A (es) 2018-05-25
CN114671952A (zh) 2022-06-28
PH12018500098A1 (en) 2018-07-09
IL256800B (en) 2022-12-01
AU2022263520A1 (en) 2022-12-08
KR102825142B1 (ko) 2025-06-26
AU2016294417A1 (en) 2018-03-08
EP3331548A1 (en) 2018-06-13
MY203911A (en) 2024-07-24
HK1249735A1 (en) 2018-11-09
EP3331548B1 (en) 2026-04-15
AU2025226796A1 (en) 2025-09-25
TN2018000021A1 (en) 2019-07-08
CN108135969A (zh) 2018-06-08
JP6826113B2 (ja) 2021-02-03
MX2023014921A (es) 2024-02-16
MY196991A (en) 2023-05-17
NZ739859A (en) 2024-08-30
IL297907B1 (en) 2024-03-01
PE20180741A1 (es) 2018-04-27
DOP2018000018A (es) 2019-10-15
RS68307B1 (en) 2026-07-31
US20240000929A1 (en) 2024-01-04
FI3331548T3 (fi) 2026-08-05
CO2018001363A2 (es) 2018-05-10
US11596689B2 (en) 2023-03-07
US12653884B2 (en) 2026-06-16
EA201890297A1 (ru) 2018-06-29
CN108135969B (zh) 2022-03-04
US20210145966A1 (en) 2021-05-20
US10874738B2 (en) 2020-12-29
GT201800018A (es) 2019-08-08
PT3331548T (pt) 2026-07-17
IL297907B2 (en) 2024-07-01
DK3331548T3 (da) 2026-06-29
MX2018000548A (es) 2018-09-26
JP7605914B2 (ja) 2024-12-24
SG10201913431QA (en) 2020-03-30
KR20180037984A (ko) 2018-04-13
EP4732909A3 (en) 2026-07-29
IL256800B2 (en) 2023-04-01
JP2021063129A (ja) 2021-04-22
IL256800A (en) 2018-03-29
US20180193454A1 (en) 2018-07-12
JP2018528258A (ja) 2018-09-27
EP3331548A4 (en) 2019-02-13
BR112018000653A2 (pt) 2018-09-18
JP2023123812A (ja) 2023-09-05
ECSP18009949A (es) 2018-10-31
CL2018000103A1 (es) 2018-06-29
JP2025038055A (ja) 2025-03-18
EP3331548B8 (en) 2026-08-05
ES3075638T3 (en) 2026-08-06
LT3331548T (lt) 2026-07-27

Similar Documents

Publication Publication Date Title
AU2022263520B2 (en) Anti-CD154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy
US9683044B2 (en) Molecules with antigen binding and polyvalent FC gamma receptor binding activity
AU2019240111A1 (en) Antibodies against signal-regulatory protein alpha and methods of use
AU2018350372B2 (en) Method
CA2992116C (en) Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy
EA051762B1 (ru) Антитело к cd154, обладающее улучшенными характеристиками связывания, функциональности и безопасности, и его применение в иммунотерапии у человека
BR112018000653B1 (pt) Anticorpo anti-cd154 humano, composição farmacêutica e usos dos mesmos
EA040553B1 (ru) Антитело к cd154, обладающее улучшенными характеристиками связывания, функциональности и безопасности, и его применение в иммунотерапии у человека

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)